| AGO-OVAR OP.4 / AGO DESKTOP OVAR III | A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery versus Chemotherapy alone for Recurrent Platinum-Sensitive Ovarian Cancer | Studie offen, Studienleiter Dr. Philipp Harter |
| LION | Die systematische pelvine und paraaortale Lymphonodektomie bei klinisch unverdächtigen LKs verbessert die Prognose epithelialer Ovarialkarzinome im Stadium IIB-IV nicht signifikant! | |
| DESKTOP III | AGO-Ovar OP.4; ENGOT-ov20; NCT01166737 | OP besser als keine OP |
| Taxol | GOG 158, GOG 162, GOG 111 | Caelyx | EORTC 55051, CALYPSO | MITO-2 |
| Hycamptin: HECTOR | Hochdosis: GOG 164 | |||
| intraperitoneale Chemotherapie: GOG 172 | Erhaltungstherapie: ABAGOVO-MAB/OVAR 10 | |||
| praeoperative Chemotherapie: EORTC 55971 | Rezidiv - Chemotherapie: MRC OV05/EORTC 55955 |
| Bevacizumab | OCEANS | OVAR 11 | GOG 0218 | ICON 7 |
| Erlotinib | EORTC 55041 | |||
| PARP Inhibitor | GOG-280 | ENGOT-OV16/NOVA | ||
| MEK-IH | Selumetinib | GOG-239 (9,10) | MEK162 | MILO |
| Tie2 - Ang1, -Ang2 -IH | AMG386 - Trial |
| Tamoxifen versus Thalidomid | GOG-198 | GOG-198 Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular en. Gynecol Oncol 119: 444-50, 2010. Hurteau JA, Brady MF, McGuire WP, Edmonds P, Darcy KM, Pearl ML, Ivanov I, Tewari K, Mannel RS, Zanotti K, Benbrook DM |
| Tamoxifen | NSGO-OC-0101 | Tamoxifen 40mg/d versus Caelyx oder Taxol weekly: PFS: Chemotherapie besser, OS: nicht signifikant! |
| GOG-198 | GOG-198 Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular en. Gynecol Oncol 119: 444-50, 2010. Hurteau JA, Brady MF, McGuire WP, Edmonds P, Darcy KM, Pearl ML, Ivanov I, Tewari K, Mannel RS, Zanotti K, Benbrook DM |
- AGO-Ovar OP.7/Trust
- Benita, Eras
- AGO-Ovar 22 /Imgyn
- AGO-Ovar 23 / Duo-o
- AGO-Ovar 2.29; 2.30;2.31 OReO
| GOG 187 | Stromazelltumoren | Cisplatin + Paclitaxel | |
| GOG-251 (8) | Rezidivierende Sex Cord Stromal Ovarian Tumors | Bevacizumab shows activity in treating recurrent sex cord stromal ovarian tumors. | Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada SD, De Geest K, Gershenson D 2012 |
| AGO ROBOT | Borderline - Tumoren | Sammelstudie mit 1236 Fällen |
Teil von
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
JCO 29(2011 suppl): Abstr LBA5006
2.) Aghajanian C, et al.:
OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).
JCO 29(2011 suppl): Abstr LBA5007
3.) Karlan BY, et al.:
Randomized, double-blind, placebo-controlled phase 2 study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
JCOncol 30(2012):362–371.
4.) Pfisterer J, et al.:
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
JCO 24(2006):4699-707.
5.) Markman M, et al.:
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
Gynecol Oncol 114(2009):195-8.
6.) Ozols RF, et al:
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study.
JCO 21(2003):3194-3200
7.) du Bois A, et al:
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
JNCI 95(2003):1320-1329
8.) Brown J, et al.:
Bevacizumab shows activity in treating recurrent sex cord stromal ovarian tumors: results of a phase II trial of the Gynecologic Oncology Group.
Gynecol Oncol 125(2012): 771-3
9.) Farley J, et al.:
A phase II trial of selumetinib (AZD6244) in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Lancet Oncol 14(2013):134-40
10.) Farley J, et al.:
A phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum.
Int J Gynecol Can 21(12): S1-S1372, 2011. (Abstract)
